AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates ...

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma ...

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

Bristol-Myers Squibb (NYSE:BMY – Free Report) had its target price boosted by Citigroup from $60.00 to $65.00 in a report published on Tuesday,Benzinga reports. They currently have a neutral rating on ...

Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...

Bristol-Myers Squibb Company (BMY) is one of the leading biopharmaceutical companies focused on developing treatments for ...

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Drugmakers have raised the list prices of more than 800 prescription drugs — ranging from blood pressure medications to cancer treatments — by a median of 4% at the start of this year, The Wall Street ...

Blue Faery is proud to announce the continuation of its annual Love Your Liver campaign during Black History Month, marking the fourth consecutive year of this impactful and award-winning initiative.

The global Continuous Thermal Monitoring Market is anticipated to grow from estimated USD 1.00 billion in 2024 to USD 1.49 billion by 2030, at a CAGR of 6.8% during the forecast period. The market is ...